What is Sellas Life Sciences Group Inc's earnings per share (EPS)?

Sellas Life Sciences Group Inc (SLS) reported diluted earnings per share of $-0.25 for fiscal year 2025. This represents a 50.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Sellas Life Sciences Group Inc Financials

SLS

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Sellas Life Sciences Group Inc (SLS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SLS FY2025 2026-05-12

SLS is functioning as a cash-funded development-stage company, with equity issuance repeatedly resetting liquidity while research drives losses.

In FY2024 and FY2025, net loss and operating cash outflow moved almost one-for-one—-$30.9M versus -$35.4M, then -$26.9M versus -$28.4M—which implies the reported losses are largely real cash consumption, not an accounting artifact. What changed in FY2025 was the balance sheet, not the operating model: $86.3M of financing cash flow lifted cash to $71.8M and left liabilities at $7.5M against $70.9M of equity.

Margin optics were not the economic driver. Gross margin stayed above 90.0% in FY2021-FY2022, but gross profit still fell from $7.4M to $900K, far below R&D and SG&A, so results were determined by development spending rather than product volume.

The balance sheet shows a sharp re-capitalization: after FY2023 ended with just $2.5M of cash, a 0.2x current ratio, and negative equity, FY2025 ended with $71.8M of cash and a 10.7x current ratio. The tradeoff is visible in the share count rising from 74.0M to 153.1M over FY2024-FY2025, meaning the stronger liquidity came from new capital, not internally generated cash.

Financial Health Signals

Financial Profile 33/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Sellas Life Sciences Group Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

100

Sellas Life Sciences Group Inc carries a low D/E ratio of 0.11, meaning only $0.11 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 10.72, Sellas Life Sciences Group Inc holds $10.72 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Returns

Sellas Life Sciences Group Inc generates a -37.9% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -326.3% the prior year.

Piotroski F-Score Weak

2/9

Sellas Life Sciences Group Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

1.06x

For every $1 of reported earnings, Sellas Life Sciences Group Inc generates $1.06 in operating cash flow (-$28.4M OCF vs -$26.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$26.9M

YoY+13.0%

Sellas Life Sciences Group Inc reported -$26.9M in net income in fiscal year 2025. This represents an increase of 13.0% from the prior year.

EPS (Diluted)

$-0.25

YoY+50.0%

Sellas Life Sciences Group Inc earned $-0.25 per diluted share (EPS) in fiscal year 2025. This represents an increase of 50.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$71.8M

YoY+417.0%

5Y CAGR+15.3%

10Y CAGR+48.3%

Sellas Life Sciences Group Inc held $71.8M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

153M

YoY+107.0%

5Y CAGR+60.8%

Sellas Life Sciences Group Inc had 153M shares outstanding in fiscal year 2025. This represents an increase of 107.0% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-37.9%

YoY+288.4pp

5Y CAGR+22.0pp

Sellas Life Sciences Group Inc's ROE was -37.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 288.4 percentage points from the prior year.

Capital Allocation

R&D Spending

$16.0M

YoY-16.1%

5Y CAGR+11.5%

10Y CAGR-3.8%

Sellas Life Sciences Group Inc invested $16.0M in research and development in fiscal year 2025. This represents a decrease of 16.1% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

SLS Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	$0-100.0%	$1.0M-86.8%	$7.6M+300.0%	$1.9M
Cost of Revenue	$0	$0	$0-100.0%	$100K-50.0%	$200K	$0
Gross Profit	N/A	N/A	$0-100.0%	$900K-87.8%	$7.4M+289.5%	$1.9M
R&D Expenses	$16.0M-16.1%	$19.1M-20.5%	$24.0M+18.4%	$20.3M+29.3%	$15.7M+68.9%	$9.3M
SG&A Expenses	$12.3M-1.3%	$12.4M-10.4%	$13.9M+10.2%	$12.6M+11.1%	$11.3M+17.9%	$9.6M
Operating Income	-$28.3M+10.3%	-$31.5M	N/A	-$42.0M-65.8%	-$25.3M-48.9%	-$17.0M
Interest Expense	N/A	N/A	$525K+65.6%	$317K+5183.3%	$6K-76.9%	$26K
Income Tax	$0	$0	$0	$0+100.0%	-$237K-1294.1%	-$17K
Net Income	-$26.9M+13.0%	-$30.9M	N/A	-$41.3M-99.5%	-$20.7M-23.5%	-$16.8M
EPS (Diluted)	$-0.25+50.0%	$-0.50+62.7%	$-1.34+37.1%	$-2.13-59.0%	$-1.34+36.5%	$-2.11

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	$0	N/A	$0	$0	$0	N/A	$0	$0
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$5.1M	N/A	$4.2M+8.9%	$3.9M+20.8%	$3.2M	N/A	$4.4M-15.9%	$5.2M
SG&A Expenses	$4.1M	N/A	$2.9M-4.5%	$3.0M+5.0%	$2.9M	N/A	$3.0M+21.8%	$2.4M
Operating Income	-$9.3M	N/A	-$7.1M-3.1%	-$6.9M-13.4%	-$6.1M	N/A	-$7.3M+3.8%	-$7.6M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$8.4M	N/A	-$6.8M-2.9%	-$6.6M-13.6%	-$5.8M	N/A	-$7.1M+4.8%	-$7.5M
EPS (Diluted)	$-0.05	N/A	$-0.06+14.3%	$-0.070.0%	$-0.07	N/A	$-0.10+23.1%	$-0.13

SLS Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$78.3M+303.2%	$19.4M+212.5%	$6.2M-70.3%	$20.9M-20.3%	$26.3M-42.9%	$46.0M
Current Assets	$75.2M+360.7%	$16.3M+414.7%	$3.2M-82.1%	$17.8M-22.9%	$23.0M-37.6%	$36.9M
Cash & Equivalents	$71.8M+417.0%	$13.9M+448.9%	$2.5M-85.2%	$17.1M-19.8%	$21.4M-39.5%	$35.3M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	$0	N/A
Goodwill	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%	$1.9M
Total Liabilities	$7.5M-25.0%	$10.0M-29.8%	$14.2M-11.8%	$16.1M+171.5%	$5.9M-67.2%	$18.1M
Current Liabilities	$7.0M-26.2%	$9.5M-30.8%	$13.7M-11.5%	$15.5M+211.4%	$5.0M-59.6%	$12.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$70.9M+648.8%	$9.5M+218.7%	-$8.0M-264.4%	$4.9M-76.2%	$20.3M-27.2%	$28.0M
Retained Earnings	-$275.0M-10.8%	-$248.1M-14.2%	-$217.2M-20.8%	-$179.9M-29.8%	-$138.6M-17.6%	-$117.9M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$114.2M+45.7%	$78.3M+52.0%	$51.6M+59.6%	$32.3M-7.6%	$35.0M+79.9%	$19.4M-26.7%	$26.5M+75.3%	$15.1M
Current Assets	$111.2M+47.8%	$75.2M+53.3%	$49.1M+66.6%	$29.4M-7.9%	$32.0M+95.8%	$16.3M-32.1%	$24.0M+95.4%	$12.3M
Cash & Equivalents	$107.1M+49.2%	$71.8M+62.0%	$44.3M+75.2%	$25.3M-10.9%	$28.4M+104.5%	$13.9M-34.0%	$21.0M+129.9%	$9.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%	$1.9M
Total Liabilities	$6.8M-9.5%	$7.5M+26.1%	$5.9M-3.8%	$6.2M-14.5%	$7.2M-27.8%	$10.0M-6.1%	$10.6M-13.1%	$12.2M
Current Liabilities	$6.5M-8.0%	$7.0M+18.4%	$5.9M-1.2%	$6.0M-12.9%	$6.9M-27.6%	$9.5M-10.4%	$10.6M-11.9%	$12.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$107.4M+51.6%	$70.9M+55.3%	$45.6M+74.5%	$26.1M-5.8%	$27.8M+193.3%	$9.5M-40.4%	$15.9M+445.6%	$2.9M
Retained Earnings	-$283.4M-3.1%	-$275.0M-2.9%	-$267.3M-2.6%	-$260.5M-2.6%	-$253.9M-2.3%	-$248.1M-2.8%	-$241.4M-3.0%	-$234.3M

SLS Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$28.4M+19.8%	-$35.4M	N/A	-$23.8M+8.5%	-$26.0M-149.8%	-$10.4M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	$0+100.0%	-$5.5M-22.2%	-$4.5M	$0	N/A
Financing Cash Flow	$86.3M+84.6%	$46.8M+109.5%	$22.3M-7.3%	$24.1M+99.4%	$12.1M-68.6%	$38.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$8.8M-79.8%	-$4.9M+30.4%	-$7.1M+3.6%	-$7.3M+19.2%	-$9.1M-26.8%	-$7.2M+8.4%	-$7.8M+19.4%	-$9.7M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	$0	$0	N/A
Financing Cash Flow	$44.1M+36.3%	$32.4M+24.2%	$26.1M+516.8%	$4.2M-82.1%	$23.6M+294662.5%	$8K-100.0%	$19.7M+4656.0%	$414K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

SLS Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	90.0%-7.4pp	97.4%-2.6pp	100.0%
Operating Margin	N/A	N/A	N/A	-4195.0%-3862.2pp	-332.8%+561.0pp	-893.8%
Net Margin	N/A	N/A	N/A	-4130.1%-3857.7pp	-272.4%+609.6pp	-881.9%
Return on Equity	-37.9%+288.4pp	-326.3%	N/A	-851.4%-749.7pp	-101.7%-41.8pp	-59.9%
Return on Assets	-34.3%+124.6pp	-158.9%	N/A	-197.2%-118.4pp	-78.8%-42.4pp	-36.4%
Current Ratio	10.72+9.0	1.72+1.5	0.23-0.9	1.14-3.5	4.63+1.6	2.99
Debt-to-Equity	0.11-0.9	1.05+2.8	-1.78-5.1	3.32+3.0	0.29-0.4	0.65
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-7.8%	N/A	-14.9%+10.4pp	-25.2%-4.3pp	-20.9%	N/A	-44.7%+211.7pp	-256.4%
Return on Assets	-7.4%	N/A	-13.2%+7.3pp	-20.4%-3.8pp	-16.6%	N/A	-26.8%+22.6pp	-49.4%
Current Ratio	17.22+6.5	10.72+2.4	8.28+3.4	4.91+0.3	4.64+2.9	1.72-0.5	2.26+1.2	1.02
Debt-to-Equity	0.06-0.0	0.11-0.0	0.13-0.1	0.24-0.0	0.26-0.8	1.05+0.4	0.67-3.5	4.19
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Tiziana Life Sciences Ltd Com TLSA

$188.3M

Elicio Therapeutics, Inc. ELTX

$189.9M

Tenaya Therapeutics, Inc. TNYA

$167.6M

COGNITION THERAPEUTICS INC CGTX

$112.8M

Entrada Therapeutics, Inc. TRDA

$254.7M

Frequently Asked Questions

Is Sellas Life Sciences Group Inc profitable?

No, Sellas Life Sciences Group Inc (SLS) reported a net income of -$26.9M in fiscal year 2025.

What is Sellas Life Sciences Group Inc's return on equity (ROE)?

Sellas Life Sciences Group Inc (SLS) has a return on equity of -37.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Sellas Life Sciences Group Inc's operating cash flow?

Sellas Life Sciences Group Inc (SLS) generated -$28.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Sellas Life Sciences Group Inc's total assets?

Sellas Life Sciences Group Inc (SLS) had $78.3M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Sellas Life Sciences Group Inc spend on research and development?

Sellas Life Sciences Group Inc (SLS) invested $16.0M in research and development during fiscal year 2025.

How many shares does Sellas Life Sciences Group Inc have outstanding?

Sellas Life Sciences Group Inc (SLS) had 153M shares outstanding as of fiscal year 2025.

What is Sellas Life Sciences Group Inc's current ratio?

Sellas Life Sciences Group Inc (SLS) had a current ratio of 10.72 as of fiscal year 2025, which is generally considered healthy.

What is Sellas Life Sciences Group Inc's debt-to-equity ratio?

Sellas Life Sciences Group Inc (SLS) had a debt-to-equity ratio of 0.11 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Sellas Life Sciences Group Inc's return on assets (ROA)?

Sellas Life Sciences Group Inc (SLS) had a return on assets of -34.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Sellas Life Sciences Group Inc's cash runway?

Based on fiscal year 2025 data, Sellas Life Sciences Group Inc (SLS) had $71.8M in cash against an annual operating cash burn of $28.4M. This gives an estimated cash runway of approximately 30 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Sellas Life Sciences Group Inc's Piotroski F-Score?

Sellas Life Sciences Group Inc (SLS) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Sellas Life Sciences Group Inc's earnings high quality?

Sellas Life Sciences Group Inc (SLS) has an earnings quality ratio of 1.06x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Sellas Life Sciences Group Inc?

Sellas Life Sciences Group Inc (SLS) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.